Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE): 7 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.3 months
D/E 0.43 · 48% dilution
Lead: Phase 3
7 candidates
N/A
7 buys · 0 sells (180d)
A transparent, data-derived signal for Cue Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$99.6M
Cash
$16.4M
Quarterly Burn
$10.9M
Runway
5.3 mo
Revenue
$5.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| bimekizumab | Phase 3 |
| cue covid-19 molecular test | — |
| cue covid-19 molecular test | — |
| CUE-101 | Phase 1 |
| CUE-102 | Phase 1 |
| CUE-401 | Preclinical |
| CUE-501 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$391
| Holder | Shares | Value |
|---|---|---|
| tidemark, llc | 1,500 | $345 |
| advisory services network, llc | 200 | $46 |
Frequently asked questions
How many drug candidates are in Cue Biopharma, Inc.'s pipeline?
Cue Biopharma, Inc. (CUE) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cue Biopharma, Inc.'s lead drug candidate?
Cue Biopharma, Inc.'s most advanced tracked candidate is bimekizumab (Phase 3) for Chronic Plaque Psoriasis.
What is Cue Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cue Biopharma, Inc. has approximately 5.3 months of cash runway.
What is Cue Biopharma, Inc.'s market capitalization?
Cue Biopharma, Inc.'s market capitalization is approximately $99.6M.
Who is the CEO of Cue Biopharma, Inc.?
Dr. Shao-Lee Lin M.D., Ph.D. is the chief executive officer of Cue Biopharma, Inc. (CUE).
Get the full picture on Cue Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.